| | english | español | français |
Go to record ID

  Home|Finding Information|Record details   Printer-friendly version

Third National Report on the implementation of the Cartagena Protocol on Biosafety
Record information and status
Record ID
109464
Status
Published
Date of creation
2015-11-30 13:45 UTC (kanelamine@hotmail.com)
Date of publication
2015-11-30 13:45 UTC (kanelamine@hotmail.com)

This document is also available in the following languages:
Origin of report
1. Country
  • Senegal
Contact officer for report
Coordinates
Monsieur Ousseynou Kassé
Directeur Exécutif de l'Autorité nationale de Biosécurité
Autorité Nationale de Biosécurité du Sénégal (ANB)
Ministère de l'Environnement et du Développement Durable, Parc Forestier de Hann, Dakar. Sénégal
Dakar
Senegal, BP 4055, Dakar
Phone:(00221) 77 5394829
Email:ouzin12@gmail.com
Consulted stakeholders
9. Organizations/stakeholders who were consulted or participated in the preparation of this report
FR
Institutions et personnes ressources membres de l'Autorité Nationale de Biosécurité et du Comité National de Biosécurité
Submission
10. Date of submission
2015-11-30
11. Time period covered by this report
Start date
2011-10-30
11. Time period covered by this report
End date
2015-10-31
Party to the Cartagena Protocol on Biosafety
Is your country a Party to the Cartagena Protocol on Biosafety (CPB)?
  • Yes
Article 2 – General provisions
14. Has your country introduced the necessary legal, administrative and other measures for the implementation of the Protocol?
This question is relevant to indicators 1.1.1, 2.1.1, 2.1.2, and 3.1.2 of the Strategic Plan
  • A domestic regulatory framework is partially in place
15. If you indicated that a national biosafety framework exists in the above question, when did it become operational?
This question is relevant to the indicator 1.1.1 of the Strategic Plan
  • 2009
16. Which specific instruments are in place for the implementation of your national biosafety framework?
  • One or more national biosafety laws
  • One or more national biosafety regulations
  • Other laws, regulations or guidelines that indirectly apply to biosafety
17. Has your country established a mechanism for the budgetary allocations of funds for the operation of its national biosafety framework?
  • Yes
18. Does your country have permanent staff to administer functions directly related to the national biosafety framework?
  • Yes
19. If you answered Yes to question 18, how many permanent staff members are in place whose functions are directly related to the national biosafety framework?
  • Less than 5
20. Has your country’s biosafety framework / laws / regulations / guidelines been submitted to the Biosafety Clearing-House (BCH)?
  • Yes
21. Here you may provide further details on the implementation of Article 2 in your country
FR
Le Sénégal a adopté la loi 2009 - 27 portant sur la biosécurité. Cette loi consacre en son article 5 la création d'une Autorité Nationale de Biosécurité (ANB) et d'un Comité National de Biosécurité (CNB). 
En 2009, deux décrets portant sur les missions, l'organisation et le fonctionnement de l'ANB et du CNB, ont été signé. L'ANB est une structure administrative composée de représentants des différents ministères concernés par la problématique de la biosécurité. Elle est chargée de faire des propositions en matière de décision sur la base du rapport scientifique d'évaluation des risques élaboré par le Comité National de Biosécurité.  Ce Comité qui regroupe entre autres quinze personnalités scientifiques choisies en raison de leurs  compétences est chargé de l'évaluation des risques liés à tout orgnaisme vivant modifié ou produit dérivé pour lequel une demande d'autorisation d'activité est soumise au Ministre en charge de l'environnement.
L'arrêté portant composition du Comité National de Biosécurité a été signé en mars 2012.
Le Directeur Exécutif de l'Autorité National de Biosécurité a été nommé en février 2014 ; toutefois, la signature du Décret portant composition de l'ANB n'est pas encore effective.
En perspective de l'intégration des dispositions du Protocole additionnel de Nagoya Kuala Lumpur et du règlement communaire de l'Union Economique et Monaitéaire de l'Afrique de l'Ouest (UEMOA), la loi nécessite une révision. En outre, dans la même dynamique, une dizaine d'arrêtés seront rédigés pour compléter la loi sur la biosécurité. Il s'agit de :
- l'arrêté fixant les conditions de transport d'OGM ou de produits dérivés ;
- l'arrêté fixant les modalités de confinement des OGM ;
- l'arrêté fixant les modalités de dissémination volontaire des OGM dans l'environnement ;
- l'arrêté fixant les conditions, principes et méthodes d'évaluation des risques liés aux OGM ;
- l'arrêté fixant les modalités de nomination et d'intervention des agents chargés du suivi et du contrôle ;
- l'arrêté fixant les conditions de destruction des OGM ou produits dérivés qui présentent des risques avérés pour la santé humaine ou animale, de même que pour la diversité biologique et l'environnement ;
- l'arrêté fixant les modalités d'étiquetage des emballages et produits commerciaux contenant des OGM ;
- l'arrêté fixant la période d'observation des OGM ou produits dérivés importés ou de production locale.    
Article 5 - Pharmaceuticals
22. Does your country regulate the transboundary movement, handling and use of living modified organisms (LMOs) which are pharmaceuticals?
  • Yes
23. If you answered Yes to question 22, has this information been submitted to the BCH?
  • No
24. Here you may provide further details on the implementation of Article 5 in your country:
FR
Les OVM qui sont des produits pharmaceutiques sont exclus du champ d'application de la loi sur la biosécurité. Ils sont pris en compte par une réglementation nationale qui leur est spécifique et qui relève d'autres accords ou organismes internationaux.
Article 6 – Transit and Contained use
25. Does your country regulate the transit of LMOs?
This question is relevant to indicator 1.8.1 of the Strategic Plan
  • Yes
26. Does your country regulate the contained use of LMOs?
This question is relevant to indicators 1.1.2 and 1.8.2 of the Strategic Plan
  • Yes
27. If you answered Yes to questions 25 or 26, has this information been submitted to the BCH?
  • Yes
28. Here you may provide further details on the implementation of Article 6 in your country:
FR
La règlementation de l'utilisation des OVM en milieu confiné est prise en compte dans l'article 2 (« champ d'application ») et dans l'article 25 (« dispositions relatives à l'utilisation d'OGM ou de produits dérivés en milieu confiné ») de la loi sur la biosécurité. La disposition de l'article 25 sera complétée par un arrêté portant modalités de confinement des OGM.
Articles 7 to 10 – Advance Informed Agreement (AIA) and intentional introduction of LMOs into the environment
29. Has your country adopted law(s) / regulations / administrative measures for the operation of the AIA procedure of the Protocol OR a domestic regulatory framework consistent with the Protocol regarding the transboundary movement of LMOs for intentional introduction into the environment?
This question is relevant to indicators 1.1.2 and 3.1.4 of the Strategic Plan
  • Yes
30. Has your country established a mechanism for taking decisions regarding first intentional transboundary movements of LMOs for intentional introduction into the environment?
  • Yes
31. If you answered Yes to question 30, does the mechanism also apply to cases of intentional introduction of LMOs into the environment that were not subject to transboundary movement?
  • Yes
32. Has your country established legal requirements for exporters under its jurisdiction to notify in writing the competent national authority of the Party of import prior to the intentional transboundary movement of an LMO that falls within the scope of the AIA procedure?
  • Yes
33. Has your country established legal requirements for the accuracy of information contained in the notification?
  • Yes
34. Has your country ever received an application / notification regarding intentional transboundary movements of LMOs for intentional introduction into the environment?
This question is relevant to indicator 1.1.4 of the Strategic Plan
  • No
35. Has your country ever taken a decision on an application / notification regarding intentional transboundary movements of LMOs for intentional introduction into the environment?
This question is relevant to indicator 1.1.5 of the Strategic Plan
  • No
38. In the current reporting period, how many applications/notifications has your country received regarding intentional transboundary movements of LMOs for intentional introduction into the environment?
  • None
39. In the current reporting period, how many decisions has your country taken regarding intentional transboundary movements of LMOs for intentional introduction into the environment?
  • None
46. Here you may provide further details on the implementation of Articles 7-10 in your country, including measures in case of lack of scientific certainty on potential adverse effects of LMOs for intentional introduction to the environment
FR
Selon l'article 4 de la loi sur la biosécurité, « par mesure de précaution, les dangers et les risques liés aux organismes génétiquement modifiés (OGM) sont évalués et circonscrits le plus tôt possible.
Lorsque des incertitudes subsistent quant à l'existence ou à la portée des risques sur la diversité biologique, la santé humaine et animale, les autorités doivent prendre des mesures de protection en attendant que la véracité et la gravité de ces risques soient pleinement démontrées.
Les autorités doivent tenir compte des principes généraux applicables à toute gestion de risques à savoir le principe de proportionnalité, le principe de non-discrimination, le principe de cohérence des mesures et celui de l'examen des avantages et des charges résultant de l'autorisation ainsi que de l'évolution des connaissances scientifiques. »
L'accord préalable en connaissance de cause constitue une des dispositions majeures de la loi sur la biosécurité du Sénégal, en partant de la notification jusqu'à la prise de décision, tout en passant par l'accusé de réception, l'évaluation des risques et la participation du public (articles 8 à 17).  
Article 11 – Procedure for living modified organisms intended for direct use as food or feed, or for processing (LMOs-FFP)
47. Has your country adopted specific law(s) or regulation(s) for decision-making regarding domestic use, including placing on the market, of LMOs-FFP?
This question is relevant to indicator 1.1.2 of the Strategic Plan
  • Yes
48. Has your country established legal requirements for the accuracy of information to be provided by the applicant?
  • Yes
49. Has your country established a mechanism to ensure that decisions regarding LMOs-FFP that may be subject to transboundary movement will be communicated to the Parties through the BCH?
This question is relevant to indicator 3.1.5 of the Strategic Plan
  • Yes
50. Has your country established a mechanism for taking decisions on the import of LMOs-FFP?
This question is relevant to indicator 1.1.2 of the Strategic Plan
  • Yes
51. Has your country indicated its needs for financial and technical assistance and capacity-building in respect of LMOs-FFP?
This question is relevant to indicator 1.2.1 of the Strategic Plan
  • No
52. Has your country ever taken a decision on LMOs-FFP (either on import or domestic use)?
  • No
58. Here you may provide further details on the implementation of Article 11 in your country, including measures in case of lack of scientific certainty on potential adverse effects of LMOs-FFP
FR
Pour les OVM destinés à être utilisés directement pour l'alimentation humaine ou animale, ou à être transformés, la loi sur la biosécurité applique la procédure d'accord préalable en connaissance de cause (article 8 à 18) en précisant à l'article 9 que la notification doit contenir les informations telles que décrites dans l'annexe 1-3 de la présente loi et les informations sur les précédentes évaluations de risques mettant surtout l'accent sur les risques sanitaires.
Par ailleurs l'article 20 stipule « qu'avant toute importation ou mise sur le marché d'organismes génétiquement modifiés ou de produits dérivés, l'utilisateur doit fournir à l'ANB une attestation de sécurité des produits et de leurs dérivés, délivrée par l'Autorité nationale Compétente du pays exportateur. Les organismes génétiquement modifiés et les produits dérivés mis au point à l'intérieur du territoire national destinés ou non à l'exportation doivent être soumis aux mêmes procédures. »

Enfin, l'alinéa 2 de l'article 4 de la loi 2009 - 27 portant sur la biosécurité dispose : " Lorsque des incertitudes subsistent quant à l'existence ou à la portée des risques sur la diversité biologique, la santé humaine et animale, les autorités doivent prendre des mesures de protection en attendant que la véracité  et la gravité de ces risques soient pleinement démontrées."
Article 12 – Review of decision
59. Has your country established a mechanism for the review and change of a decision regarding an intentional transboundary movement of LMOs?
  • Yes
60. Has your country ever received a request for a review of a decision?
  • No
61. Has your country ever reviewed / changed a decision regarding an intentional transboundary movement of LMOs?
  • Yes, decision reviewed
62. In the current reporting period, how many decisions were reviewed and/or changed regarding an intentional transboundary movement of an LMO?
  • None
66. Here you may provide further details on the implementation of Article 12 in your country
FR
Selon l'article 14 de la loi sur la biosécurité, en cas de circonstances nouvelles, « sur la base de nouvelles informations scientifiques sur les effets défavorables potentiels sur la conservation et l'utilisation durable de la diversité biologique, de la santé humaine et animale, le Ministre en charge de l'Environnement peut, sur proposition de l'ANB, à tout moment, reconsidérer et modifier sa décision concernant une demande d'autorisation d'activités liées aux organismes génétiquement modifiés ou produits dérivés.

Dans de telles circonstances, le Ministre en charge de l'Environnement peut, sur proposition de l'ANB, aux frais du titulaire de l'autorisation ou des détenteurs des organismes génétiquement modifiés ou produits dérivés :
- suspendre l'autorisation dans l'attente d'informations complémentaires et, s'il y a lieu, ordonner le retrait des produits de la vente en en interdire l'utilisation ;
- imposer des modifications aux conditions de dissémination volontaire ;
- ordonner la destruction des organismes génétiquement modifiés ou produits dérivés et, en cas de carence du titulaire de l'autorisation ou du détenteur y faire procéder d'office.

Sauf en cas d'urgence, ces mesures ne peuvent intervenir que si le titulaire a été mis à même de présenter ses observations.

Si les mesures prévues ci-dessus ne permettent pas de supprimer ou minimiser les risques l'Autorité nationale compétente procède au retrait de l'autorisation. »
Article 13 – Simplified procedure
67. Has your country established a system for the application of the simplified procedure regarding an intentional transboundary movement of LMOs?
  • No
68. Has your country ever applied the simplified procedure?
  • No
70. In the current reporting period, how many LMOs has your country applied the simplified procedure to?
  • None
71. Here you may provide further details on the implementation of Article 13 in your country
FR
Selon les dispositions de la loi sur la biosécurité, tous les organismes génétiquement modifiés et leurs produits dérivés sont soumis à la procédure d'accord préalable en connaissance de cause.
Article 14 – Bilateral, regional and multilateral agreements and arrangements
72. Has your country entered into any bilateral, regional or multilateral agreements or arrangements?
  • Yes
73. If you answered Yes to question 72, how many LMO-related collaborative bilateral/multilateral arrangements has your country established with other Parties/non-Parties?
This question is relevant to indicator 1.2.8 of the Strategic Plan
  • One or more
74. If you answered Yes to question 72, has your country informed the Parties through the BCH of the agreements or arrangements?
This question is relevant to indicator 3.1.5 of the Strategic Plan
  • No
75. If you answered Yes to question 72, please provide a brief description of the scope and objective of the agreements or arrangements entered into
FR
Le Règlement communautaire de biosécurité de l'UEMOA  (qui va bientôt entrer en vigueur) s'applique à toute utilisation y compris les mouvements transfrontières, le transit, la manipulation d'organismes vivants modifiés et/ou  produits dérivés qui pourraient avoir des effets défavorables sur l'environnement, et en particulier sur la conservation et l'utilisation durable de la diversité biologique, sur la santé humaine et animale.
76. Here you may provide further details on the implementation of Article 14 in your country
FR
Le Sénégal a adhéré au Règlement communautaire de biosécurité de l'UEMOA qui a fait l'objet d'un examen en février 2015 (à Ougadougou), par les experts des Etats parties de l'UEMOA et d'une approbation par les Ministres sectoriels (concernés par la biosécurité). Toutefois, en l'absence d'adoption (par le Conseil des Ministres) et de l'entrée en vigueur du Règlement communautaire (qui est en cours d'adoption), l'information n'a pas été publiée au BCH.
Articles 15 & 16 – Risk Assessment and Risk Management
77. Has your country established a national framework for conducting risk assessments prior to taking decisions regarding LMOs?
  • Yes
78. If you answered Yes to question 77, does this framework include procedures for identifying and/or training national experts to conduct risk assessments?
  • Yes
79. How many people in your country have been trained in risk assessment, monitoring, management and control of LMOs?
This question is relevant to indicator 2.2.3 of the Strategic Plan
a) Risk assessment:
  • 50 or more
b) Management / Control:
  • 50 or more
c) Monitoring:
  • 50 or more
80. Is your country using training material and/or technical guidance for training in risk assessment and risk management of LMOs?
This question is relevant to indicator 2.2.5 of the Strategic Plan
  • Yes
81. Is your country using the "Manual on Risk Assessment of LMOs" (developed by CBD Secretariat) for training in risk assessment?
This question is relevant to indicator 2.2.5 of the Strategic Plan
  • No
82. Is your country using the "Guidance on Risk Assessment of LMOs" (developed by the Online Forum and the AHTEG on Risk Assessment and Risk Management) for training in risk assessment?
This question is relevant to indicator 2.2.5 of the Strategic Plan
  • No
83. Are the currently available training materials or technical guidance on risk assessment and/or risk management of LMOs sufficient?
This question is relevant to indicator 2.2.6 of the Strategic Plan
  • No
84. Does your country have the capacity to detect, identify, assess and/or monitor living modified organisms or specific traits that may have adverse effects on the conservation and sustainable use of biological diversity, taking into account risks to human health?
This question is relevant to indicators 1.4.2 and 1.6.3 of the Strategic Plan
a) Detect:
  • Yes
b) Identify:
  • Yes
c) Assess:
  • Yes
d) Monitor:
  • Yes
85. Has your country adopted or used any guidance documents for the purpose of conducting risk assessment or risk management, or for evaluating risk assessment reports submitted by notifiers?
This question is relevant to indicators 1.3.1 of the Strategic Plan
a) Risk assessment:
  • No
b) Risk management:
  • No
86. Is your country using the "Guidance on Risk Assessment of LMOs" (developed by the Online Forum and the AHTEG on Risk Assessment and Risk Management) for conducting risk assessment or risk management, or for evaluating risk assessment reports submitted by notifiers?
This question is relevant to indicator 2.2.5 of the Strategic Plan
  • No
87. Has your country adopted any common approaches to risk assessment with other countries?
This question is relevant to indicator 1.3.2 of the Strategic Plan
  • Yes
88. Has your country cooperated with other Parties with a view to identifying LMOs or specific traits that may have adverse effects on the conservation and sustainable use of biological diversity?
This question is relevant to indicator 1.4.1 of the Strategic Plan
  • Yes
89. Has your country ever conducted a risk assessment of an LMO including any type of risk assessment of LMOs, e.g. for contained use, field trials, commercial purposes, direct use as food, feed, or for processing?
This question is relevant to indicator 1.3.3 of the Strategic Plan
  • No
94. Has your country taken measures to ensure that any LMO, whether imported or locally developed, undergoes an appropriate period of observation that is commensurate with its life-cycle or generation time before it is put to its intended use?
  • Yes
95. Has your country established a mechanism for monitoring potential effects of LMOs that are released into the environment?
  • Yes
96. Does your country have the infrastructure (e.g. laboratory facilities) for monitoring or managing LMOs?
This question is relevant to indicator 2.2.4 of the Strategic Plan
  • Yes
97. Here you may provide further details on the implementation of Articles 15 and 16 in your country
FR
Au Sénégal, d'importants efforts de enforcement des capacités sur l'évaluation et la gestion des risques liés aux OGM, ont été fournis à l'endroit des membres de l'Autorité Nationale de Biosécurité et du Comité national de biosécurité. Le pays dispose également d'un laboratoire national de biosécurité avec une expertise et un niveau d'équipement adéquats.
Dans la loi sur la biosécurité, les dispositions relatives à l'évaluation et la gestion des risques liés aux OGM sont déclinées à travers plusieurs articles (article 11,  articles 38 à 44), et au niveau de l'annexe 2 de ladite loi. Un arrêté complémentaire est prévu pour en préciser les modalités.
Article 17 – Unintentional transboundary movements and emergency measures
98. Has your country established and maintained appropriate measures to prevent unintentional transboundary movements of LMOs?
  • Yes, to some extent
Here you may provide further details
FR
Pour la prévention des mouvements transfrontières non intentionnel, des dispositions générales de mise en place de mesures d'urgence sont inscrites dans la loi sur la biosécurité. Toutefois, le dispositif n'est pas encore testé pour évaluer son niveau d'opérationnalité.
99. Has your country established a mechanism for addressing emergency measures in case of unintentional transboundary movements of LMOs that are likely to have significant adverse effect on biological diversity?
  • Yes, to some extent
Here you may provide further details
FR
idem que ci-dessus
100. Does your country have the capacity to take appropriate measures in the event that an LMO is unintentionally released?
This question is relevant to indicator 1.8.3 of the Strategic Plan
  • No
101. In the current reporting period, how many times has your country received information concerning occurrences that led, or may have led, to unintentional transboundary movement(s) of one or more LMOs to or from territories under its jurisdiction?
  • Never
105. Here you may provide further details on the implementation of Article 17 in your country
FR
En cas de survenue d'accidents et de mouvements transfrontières non intentionnels, la loi sur la biosécurité a prévu la mise en œuvre de mesures de sécurité et de plans d'urgence (articles 38 à 44).
Article 18 – Handling, transport, packaging and identification
106. Has your country taken measures to require that LMOs that are subject to transboundary movement are handled, packaged and transported under conditions of safety, taking into account relevant international rules and standards?
  • Yes
107. Has your country taken measures to require that documentation accompanying LMOs-FFP clearly identifies that, in cases where the identity of the LMOs is not known through means such as identity preservation systems, they may contain living modified organisms and are not intended for intentional introduction into the environment, as well as a contact point for further information?
This question is relevant to indicator 1.6.1 of the Strategic Plan
  • Yes
108. Has your country taken measures to require that documentation accompanying LMOs-FFP clearly identifies that, in cases where the identity of the LMOs is known through means such as identity preservation systems, they contain living modified organisms and are not intended for intentional introduction into the environment, as well as a contact point for further information?
This question is relevant to indicator 1.6.1 of the Strategic Plan
  • Yes
109. If you answered Yes or Yes, to some extent to question(s) 107 and/or 108, what type of documentation does your country require for the identification of LMOs-FFP?
  • Existing or a stand-alone document
110. Has your country taken measures to require that documentation accompanying LMOs that are destined for contained use clearly identifies them as living modified organisms and specifies any requirements for the safe handling, storage, transport and use, the contact point for further information, including the name and address of the individual and institution to whom the LMO are consigned?
This question is relevant to indicator 1.6.2 of the Strategic Plan
  • Yes
111. If you answered Yes or Yes, to some extent to question 110, what type of documentation does your country require for the identification of LMOs that are destined for contained?
  • Existing or a stand-alone document
112. Has your country taken measures to require that documentation accompanying LMOs that are intended for intentional introduction into the environment of the Party of import, clearly identifies them as living modified organisms; specifies the identity and relevant traits and/or characteristics, any requirements for the safe handling, storage, transport and use, the contact point for further information and, as appropriate, the name and address of the importer and exporter; and contains a declaration that the movement is in conformity with the requirements of this Protocol applicable to the exporter?
This question is relevant to indicator 1.6.2 of the Strategic Plan
  • Yes
113. If you answered Yes or Yes, to some extent to question 112, what type of documentation does your country require for the identification of LMOs that are intended for intentional introduction into the environment?
  • Existing or a stand-alone document
114. Does your country have available any guidance for the purpose of ensuring the safe handling, transport, and packaging of living modified organisms?
This question is relevant to indicator 1.6.4 of the Strategic Plan
  • Yes
115. Does your country have the capacity to enforce the requirements of identification and documentation of LMOs?
  • Yes
116. How many customs officers in your country have received training in the identification of LMOs?
This question is relevant to indicator 2.3.1 of the Strategic Plan
  • None
117. Has your country established procedures for the sampling and detection of LMOs?
  • Yes, to some extent
118. How many laboratory personnel in your country have received training in detection of LMOs?
This question is relevant to indicator 2.3.1 of the Strategic Plan
  • One or more
119. Does your country have reliable access to laboratory facilities for the detection of LMOs?
This question is relevant to indicator 2.3.2 of the Strategic Plan
  • Yes
120. How many laboratories in your country are certified for LMO detection?
This question is relevant to indicator 2.3.3 of the Strategic Plan
  • One or more
121. How many of the certified laboratories in the previous question are currently operating in the detection of LMOs?
This question is relevant to indicator 2.3.4 of the Strategic Plan
  • One or more
122. Here you may provide further details on the implementation of Article 18 in your country:
FR
Dans la loi sur la biosécurité, des dispositions générales concernent la manipulation, le transport et l'emballage des OGM. Il est prévu de compléter ces dispositions générales par des arrêtés qui préciseront les modalités de leur mise en œuvre. Pour l'identification des OGM, le Sénégal dispose d'un laboratoire national de référence en matière de biosécurité (qui a bénéficié d'un important appui en équipement de la part de l'Union Economique et Monétaire Ouest Africaine). En outre, des bases de  coopération sont établies entre le Ministère en Charge de la biosécurité (Ministère de l'Environnement et du Développement Durable) et d'autres ministères comme le Ministère du Commerce et le Ministère de l'Economie et des Finances (en charge des services de la douane) qui ont leurs représentants dans le Comité National de Biosécurité et dans l'Autorité nationale de Biosécurité. 
Article 19 – Competent National Authorities and National Focal Points
123. In case your country has designated more than one competent national authority, has your country established a mechanism for the coordination of their actions prior to taking decisions regarding LMOs?
  • Not applicable
124. Has your country established adequate institutional capacity to enable the competent national authority(ies) to perform the administrative functions required by the Cartagena Protocol on Biosafety?
  • Yes, to some extent
125. Here you may provide further details on the implementation of Article 19 in your country
FR
Le pays dispose d'une Autorité nationale de Biosécurité (ANB), comme autorité nationale compétente qui a en charge toutes les fonctions nécessaires à la mise en œuvre du Protocole de Cartagena, les fonctions administratives de décisions sur les OGM et un rôle de sensibilisation. L'ANB intègre en son sein l'ensemble des secteurs étatiques concernés par la gestion sécurisée des OGM (y compris un représentant du Codex Alimentarus) et des représentants de la société civile. 
L'ANB s'appuie sur le Comité national de Biosécurité, en tant qu'organe consultatif d'avis scientifique et technique.
En outre, pour la gestion de l'information relative à la prévention des risques biotechnologiques et pour faciliter les orientations de renforcement des capacités, le Sénégal a également nommé un correspondant national (qui est membre de l'ANB) pour le BCH et pour le Protocole de Cartagena.
L'insuffisance de l'allocation budgétaire et de l'autonomie de gestion, ainsi que le déficit de personnel et d'infrastructures constituent pour l'ANB, un handicap qu'il convient de corriger pour assurer un meilleur fonctionnement.
Article 20 – Information Sharing and the Biosafety Clearing-House (BCH)
126. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH.
This question is relevant to indicator 3.1.5 of the Strategic Plan
a) Existing national legislation, regulations and guidelines for implementing the Protocol, as well as information required by Parties for the advance informed agreement procedure (Article 20, paragraph 3 (a))
  • Information available and in the BCH
b) National laws, regulations and guidelines applicable to the import of LMOs intended for direct use as food or feed, or for processing (Article 11, paragraph 5)
  • Information available and in the BCH
c) Bilateral, multilateral and regional agreements and arrangements (Articles 14, paragraph 2 and 20, paragraph 3 (b))
  • Information available but not in the BCH
d) Contact details for competent national authorities (Article 19, paragraphs 2 and 3), national focal points (Article 19, paragraphs 1 and 3), and emergency contacts (Article 17, paragraph 3 (e))
  • Information available and in the BCH
e) Reports submitted by the Parties on the operation of the Protocol (Article 20, paragraph 3 (e))
  • Information available and in the BCH
f) Decisions by a Party on regulating the transit of specific living modified organisms (LMOs) (Article 6, paragraph 1)
  • Information not available
g) Occurrence of unintentional transboundary movements that are likely to have significant adverse effects on biological diversity (Article 17, paragraph 1)
  • Information not available
h) Illegal transboundary movements of LMOs (Article 25, paragraph 3)
  • Information not available
i) Final decisions regarding the importation or release of LMOs (i.e. approval or prohibition, any conditions, requests for further information, extensions granted, reasons for decision) (Articles 10, paragraph 3 and 20, paragraph 3(d))
  • Information not available
j) Information on the application of domestic regulations to specific imports of LMOs (Article 14, paragraph 4)
  • Information not available
k) Final decisions regarding the domestic use of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing (Article 11, paragraph 1)
  • Information not available
l) Final decisions regarding the import of LMOs intended for direct use as food or feed, or for processing that are taken under domestic regulatory frameworks (Article 11, paragraph 4) or in accordance with annex III (Article 11, paragraph 6) (requirement of Article 20, paragraph 3(d))
  • Information not available
m) Declarations regarding the framework to be used for LMOs intended for direct use as food or feed, or for processing (Article 11, paragraph 6)
  • Information not available
n) Review and change of decisions regarding intentional transboundary movements of LMOs (Article 12, paragraph 1)
  • Information not available
o) LMOs granted exemption status by each Party (Article 13, paragraph 1)
  • Information not available
p) Cases where intentional transboundary movement may take place at the same time as the movement is notified to the Party of import (Article 13, paragraph 1)
  • Information not available
q) Summaries of risk assessments or environmental reviews of LMOs generated by regulatory processes and relevant information regarding products thereof (Article 20, paragraph 3 (c))
  • Information not available
127. Has your country established a mechanism for strengthening the capacity of the BCH National Focal Point to perform its administrative functions?
  • Yes
128. Has your country established a mechanism for the coordination among the BCH National Focal Point, the Cartagena Protocol focal point, and the competent national authority(ies) for making information available to the BCH?
  • Yes
129. Does your country use the information available in the BCH in its decision making processes on LMOs?
  • Not applicable
130. Has your country experienced difficulties accessing or using the BCH?
This question is relevant to indicator 4.1.8 of the Strategic Plan
  • No
131. Is the information submitted by your country to the BCH complete and up-to date?
  • Yes
132. Please indicate the number of regional, national and international events organized in relation to biosafety (e.g. seminars, workshops, press conferences, educational events, etc.,) in the last 2 years:
This question is relevant to indicator 4.3.1 of the Strategic Plan
  • 5 or more
133. Please indicate the number of biosafety related publications that has been made available in your country in the last year:
This question is relevant to indicator 4.3.2 of the Strategic Plan
  • None
135. Here you may provide further details on the implementation of Article 20 in your country
FR
Dans le cadre du projet BCH 2 du FEM et d'autres sessions de formation financées par des partenaires, le Sénégal a bénéficié d'un important renforcement des capacités sur le BCH. Un nœud Hermes a été établi avec le BCH central et a permis la création d'un BCH national qui reste encore peu opérationnel et nécessite une meilleure prise en charge. Le déficit noté dans la vulgarisation du BCH (central ou national) a conduit à des gaps dans l'échange et la gestion de l'information sur la prévention des risques biotechnologiques. Une meilleure organisation est à rechercher, pour rendre plus accessible et plus fonctionnel le BCH national et lui faire jouer pleinement son rôle.
Article 21 – Confidential information
136. Has your country established procedures to protect confidential information received under the Protocol?
  • Yes
137. Does your country allow the notifier to identify information that is to be treated as confidential?
  • Yes, always
138. Here you may provide further details on the implementation of Article 21 in your country
FR
Au niveau de la loi sur la biosécurité, l'Article 30 stipule que : « l'Autorité Nationale de Biosécurité permet au notifiant de demander qu'une information qui lui est fournie soit considérée comme confidentielle.
L'ANB décide de la recevabilité de la demande de confidentialité de l'information.
Lorsque la demande est rejetée, l'ANB doit en informer le notifiant en fournissant les motifs justifiant l'irrecevabilité de la demande. »

En outre, au niveau de l'article 31 précise : qu'en « cas de retrait d'une notification, l'Autorité Nationale de Biosécurité respecte la confidentialité des informations. L'ANB ne divulgue pas à une tierce personne ni utilise les informations fournies par le notifiant à des fins non autorisées par la présente loi.
L'ANB veille à assurer la protection des informations au niveau des personnes chargées de les recueillir.
L'ANB veille à respecter la confidentialité des informations protégées par des droits de propriété intellectuelle, sauf si ces informations sont nécessaires à l'évaluation des risques. »
Article 22 – Capacity-building
139. Does your country have predictable and reliable funding for building capacity for the effective implementation of the Protocol?
This question is relevant to indicator 1.2.6 and 3.1.8 of the Strategic Plan
  • No
140. Has your country received external support or benefited from collaborative activities with other Parties in the development and/or strengthening of human resources and institutional capacities in biosafety?
  • Yes
141. If you answered Yes to question 140, how were these resources made available?
  • Regional channels
142. Has your country provided support to other Parties in the development and/or strengthening of human resources and institutional capacities in biosafety?
  • No
144. Has your country ever initiated a process to access GEF funds for building capacity in biosafety?
  • Yes
145. If you answered Yes to question 144, how would you characterize the process?
Please add further details about your experience in accessing GEF funds under question 157.
  • Average
146. Has your country ever received funding from the GEF for building capacity in biosafety?
  • Pilot Biosafety Enabling Activity
  • Development of national biosafety frameworks
  • Building Capacity for Effective Participation in the BCH (Phase II)
147. During the current reporting period, has your country undertaken activities for the development and/or strengthening of human resources and institutional capacities in biosafety?
  • Yes
148. If you answered Yes to question 147, in which of the following areas were these activities undertaken?
  • Human resources capacity development and training
  • Risk assessment and other scientific and technical expertise
  • Risk management
  • Public awareness, participation and education in biosafety
  • Information exchange and data management including participation in the Biosafety Clearing-House
  • Scientific, technical and institutional collaboration at subregional, regional and international levels
  • Identification of LMOs, including their detection
  • Socio-economic considerations
  • Implementation of the documentation requirements under Article 18.2 of the Protocol
  • Scientific biosafety research relating to LMOs
  • Taking into account risks to human health
149. During the current reporting period, has your country carried out a capacity-building needs assessment?
This question is relevant to indicator 1.2.1 of the Strategic Plan
  • No
151. Does your country still have capacity-building needs?
This question is relevant to indicator 1.2.7 of the Strategic Plan
  • Yes
152. If you answered Yes to question 151, indicate which of the following areas still need capacity-building.
  • Institutional capacity
  • Human resources capacity development and training
  • Risk assessment and other scientific and technical expertise
  • Risk management
  • Public awareness, participation and education in biosafety
  • Information exchange and data management including participation in the Biosafety Clearing-House
  • Scientific, technical and institutional collaboration at subregional, regional and international levels
  • Technology transfer
  • Identification of LMOs, including their detection
  • Socio-economic considerations
  • Implementation of the documentation requirements under Article 18.2 of the Protocol
  • Handling of confidential information
  • Measures to address unintentional and/or illegal transboundary movements of LMOs
  • Scientific biosafety research relating to LMOs
153. Has your country developed a capacity-building strategy or action plan?
This question is relevant to indicator 1.2.2 of the Strategic Plan
  • No
154. Does your country have in place a functional national mechanism for coordinating biosafety capacity-building initiatives?
This question is relevant to indicator 1.2.4 of the Strategic Plan
  • No
155. How many biosafety short-term training programmes and/or academic courses are offered annually in your country?
This question is relevant to indicator 1.2.3 of the Strategic Plan
  • 1 per year or more
156. Has your country submitted the details of national biosafety experts to the Roster of Experts in the BCH?
  • No
157. Here you may provide further details on the implementation of Article 22 in your country, including further details about your experience in accessing GEF funds
FR
Malgré le principe STAR du FEM et les recommandations des décisions de la COP-MOP préconisant une bonne prise en charge de la prévention des risques biotechnologiques par les Etats Parties au Protocole, il est noté une absence de mobilisation de ressources du FEM en faveur du cadre national de biosécurité en particulier. Une meilleure organisation du système national d'allocation des ressources du FEM, est nécessaire pour une bonne prise en compte du cadre national de biosécurité.
Article 23 – Public awareness and participation
158. Has your country established a strategy or put in place legislation for promoting and facilitating public awareness, education and participation concerning the safe transfer, handling and use of LMOs?
  • Yes, to some extent
159. Has your country designed and/or implemented an outreach/communication strategy on biosafety?
This question is relevant to indicator 5.3.2 of the Strategic Plan
  • No
160. Does your country have any awareness and outreach programmes on biosafety?
This question is relevant to indicator 5.3.1 of the Strategic Plan
  • No
162. Has your country established a biosafety website searchable archives, national resource centres or sections in existing national libraries dedicated to biosafety educational materials?
This question is relevant to indicators 2.5.3 and 5.3.3 of the Strategic Plan
  • No
163. How many collaborative initiatives (including joint activities) on the Cartagena Protocol and other Conventions and processes has your government established in the last 4 years?
This question is relevant to indicator 5.2.1 of the Strategic Plan
  • One or more
164. Has your country established a mechanism to ensure public access to information on living modified organisms that may be imported?
  • Yes, to some extent
165. Has your country established a mechanism to consult the public in the decision-making process regarding LMOs?
This question is relevant to indicator 2.5.1 of the Strategic Plan
  • Yes
166. Has your country established a mechanism to make available to the public the results of decisions taken on LMOs?
This question is relevant to indicator 2.5.1 of the Strategic Plan
  • Yes
167. Has your country informed the public about existing modalities for public participation in the decision-making process regarding living modified organisms?
This question is relevant to indicator 2.5.2 of the Strategic Plan
  • Yes, to some extent
170. Has your country taken any initiative to inform its public about the means of public access to the Biosafety Clearing-House?
  • Yes
171. How many academic institutions in your country are offering biosafety education and training courses and programmes?
This question is relevant to indicator 2.7.1 of the Strategic Plan
  • One or more
172. Please indicate the number of educational materials and/or online modules on biosafety that are available and accessible to the public in your country:
This question is relevant to indicators 2.7.2 and 5.3.4 of the Strategic Plan
  • One or more
173. In the current reporting period, has your country promoted and facilitated public awareness, education and participation concerning the safe transfer, handling and use of LMOs?
  • Yes, to some extent
174. If you answered Yes to question 173, has your country cooperated with other States and international bodies?
  • No
175. In the current reporting period, how many times has your country consulted the public in the decision-making process regarding LMOs and made the results of such decisions available to the public?
  • Never
Article 24 – Non-Parties
177. Has your country entered into any bilateral, regional, or multilateral agreement with non-Parties regarding transboundary movements of LMOs?
  • No
178. Has your country ever imported LMOs from a non-Party?
  • No
179. Has your country ever exported LMOs to a non-Party?
  • No
Article 25 – Illegal transboundary movements
184. Has your country adopted domestic measures aimed at preventing and/or penalizing transboundary movements of LMOs carried out in contravention of its domestic measures to implement this Protocol?
  • Yes
185. Has your country established a strategy for detecting illegal transboundary movements of LMOs?
  • No
186. In the current reporting period, how many times has your country received information concerning cases of illegal transboundary movements of an LMO to or from territories under its jurisdiction?
If you replied Never to question 186 please go to question 191
  • Never
Article 26 – Socio-economic considerations
192. Does your country have any specific approaches or requirements that facilitate how socio-economic considerations should be taken into account in LMO decision making?
This question is relevant to indicator 1.7.2 of the Strategic Plan
  • Yes
193. If your country has taken a decision on import, has it ever taken into account socio-economic considerations arising from the impact of the LMO on the conservation and sustainable use of biological diversity?
  • Not applicable
194. How many peer-reviewed published materials has your country used for the purpose of elaborating or determining national actions with regard to socio-economic considerations?
This question is relevant to indicator 1.7.1 of the Strategic Plan
  • None
196. Has your country cooperated with other Parties on research and information exchange on any socio-economic impacts of LMOs?
  • Yes, to some extent
197. Here you may provide further details on the implementation of Article 26 in your country
FR
Des visites d'échange et des sessions de renforcement de capacités ont été effectuées au Burkina Faso et ont permis d'être édifiées sur des problématiques telles que la prise en compte des considérations socio-économiques dans les décisions.
Article 27 – Liability and Redress
198. Has your country ratified or acceded to the Nagoya-Kuala Lumpur Supplementary Protocol on Liability and Redress?
  • No
199. If you answered No to question 198, is there any national process in place towards becoming a Party?
  • Yes
200. Has your country received any financial and/or technical assistance for capacity-building in the area of liability and redress relating to living modified organisms?
This question is relevant to indicator 2.4.1 of the Strategic Plan
  • No
201. Does your country have administrative or legal instrument that provide for response measures for damage to biodiversity resulting from living modified organisms?
This question is relevant to indicators 1.5.2 and 2.4.2 of the Strategic Plan
  • Yes
202. Here you may provide further details on any activities undertaken in your country towards the implementation of the Nagoya-Kuala Lumpur Supplementary Protocol on Liability and Redress
FR
Le Protocole additionnel de Nagoya-Kuala Lumpur, bien que signé par le Sénégal, n'est toutefois pas encore ratifié. Dans ce domaine, il existe un réel besoin de renforcement de capacités.
Article 28 – Financial Mechanism and Resources
203. How much additional funding (in the equivalent of US dollars) has your country mobilized in the last four years to support implementation of the Biosafety Protocol, beyond the regular national budgetary allocation?
This question is relevant to indicator 1.2.5 of the Strategic Plan
  • 100,000 USD or more
Article 33 – Monitoring and reporting
204. Does your country have in place a monitoring and/or an enforcement system for the implementation of the Cartagena Protocol?
This question is relevant to indicator 3.1.6 of the Strategic Plan
a) Monitoring system:
  • Yes
b) Enforcement system:
  • Yes
205. Has your country submitted all the previous due National Reports?
  • Yes